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A B S T R A C T
Objective: Previous HPV models have only included genital transmission, when evidence suggests that trans-
mission between several anatomical sites occurs. We compared model predictions of population-level HPV
vaccination eﬀectiveness against genital HPV16 infection in women, using a 1) uni-site (genital site), and a 2)
multi-site model (genital and one extragenital site).
Methods: We developed a uni-site and a multi-site deterministic HPV transmission model, assuming natural
immunity was either site-speciﬁc or systemic. Both models were calibrated to genital HPV16 prevalence
(5%–7.5%), whilst the multi-site model was calibrated to HPV16 prevalence representative of oral (0%–1%) and
anal (1%–7.5%) sites. For each model, we identiﬁed 2500 parameter sets that ﬁt endemic genital and extra-
genital prevalences within pre-speciﬁed target ranges. In the Base-case analysis, vaccination was girls-only with
40% coverage. Vaccine eﬃcacy was 100% for all sites with lifetime protection. The outcome was the relative
reduction in genital HPV16 prevalence among women at post-vaccination equilibrium (RRprev). RRprev was
stratiﬁed by extragenital prevalence pre-vaccination.
Results: Under assumptions of site-speciﬁc immunity, RRprev with the multi-site model was generally greater
than with the uni-site model. Diﬀerences between the uni-site and multi-site models were greater when trans-
mission from the extragenital site to the genital site was high. Under assumptions of systemic immunity, the
multi-site and uni-site models yielded similar RRprev in the scenario without immunity after extragenital in-
fection. In the scenario with systemic immunity after extragenital infection, the multi-site model yielded lower
predictions of RRprev than the uni-site model.
Conclusions: Modelling genital-site only transmission may overestimate vaccination impact if extragenital in-
fections contribute to systemic natural immunity or underestimate vaccination impact if a high proportion of
genital infections originate from extragenital infections. Under current understanding of heterosexual HPV
transmission and immunity, a substantial bias from using uni-site models in predicting vaccination eﬀectiveness
against genital HPV infection is unlikely to occur.
1. Introduction
Human papillomavirus (HPV) is a sexually transmitted infection
(STI), able to infect the basal epithelial layer of the cervix, oral cavity,
the anus and the genitals. The main focus of HPV related research and
prevention has historically been cervical cancer, for which HPV is the
necessary cause. This is mainly because cervical cancers account for an
estimated 87% of all HPV-attributable cancers worldwide (Forman
et al., 2012). However, research on non-cervical HPV infections and
disease has dramatically increased since 2005. Two main reasons
explain this intensiﬁed focus on non-cervical HPV: 1) a steep increase in
the incidence of oropharyngeal and anal cancers in the US and other
high income countries (Forman et al., 2012; Gillison et al., 2012a) and
2) recent results showing that HPV vaccines are highly eﬀective at
preventing persistent HPV infection and pre-cancerous lesions in sites
other than the cervix (Munoz et al., 2010; Goldstone et al., 2013;
Herrero et al., 2013; Gillison et al., 2014).
Despite the recent focus on non-cervical HPV research, there remain
signiﬁcant gaps in knowledge, particularly around HPV transmission to
and immunity between cervical and non-cervical sites. The few
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epidemiological studies on multi-site HPV infection/transmission sug-
gest that autoinoculation within one host, or inter-site transmission
between individuals may occur (Heijne et al., 2017; Hernandez et al.,
2008; Vogt et al., 2013). Plausible modes of inter-site transmission in-
clude oral sex, anal sex, or indirect transmission through contact with
hands. Autoinoculation between the genital and oral or anal sites could
occur through intermediate contact with the hands (Cook, Thompson El
Fau - Kelso et al.; Simpson, Blomﬁeld et al.) or through virus shedding
in the anogenital region (Goodman, Shvetsov Yb Fau - McDuﬃe et al.).
Therefore, HPV infection at one site is likely dependent on transmission
from other sites. As for natural immunity, studies suggest that pro-
duction of antibodies is much more frequent following cervical infec-
tions than non-cervical infections (Carter et al., 2000; Giuliano et al.,
2015). However, it is unclear whether antibody response is synonymous
with systemic protection against subsequent infections at other sites.
Furthermore, the role of local immunity, either humoral or cell-medi-
ated, in protecting against subsequent infections is not well understood.
Hence, there could be site-speciﬁc diﬀerences in immune response and
vulnerability to subsequent infections.
None of the 19 HPV transmission-dynamic models developed over
the past 10 years to assess HPV vaccination eﬀectiveness (Brisson et al.,
2015) have incorporated multi-site infections/transmission, which may
have biased their predictions. Indeed, all previous models were “uni-
site” models, where infection is only acquired and transmitted at one
site in women (implicitly the cervico-vaginal region) and men (im-
plicitly the penis). Furthermore, the bulk of previous models were only
ﬁt to age-speciﬁc HPV infection data at the cervico-vaginal site (Canfell
et al., 2012). By ignoring other potential markers of infection and
sources of transmission from extragenital infections, these uni-site
models may be biased in their predictions of long term post HPV vac-
cination dynamics (e.g., herd eﬀects and population-level eﬀective-
ness).
Given that the predictions of previous HPV models, based on a uni-
site transmission paradigm, were highly inﬂuential in HPV vaccination
policy decisions worldwide (Jit and Brisson, 2011), it is important to
assess the robustness of the predictions to assumptions about multi-site
transmission and natural immunity. The objectives of this study are to:
1) compare predictions of HPV16 vaccination eﬀectiveness and herd
eﬀects between multi-site and uni-site transmission-dynamic models,
under various assumptions of HPV16 transmission and natural im-
munity, and 2) understand the eﬀect of the key factors of transmission
responsible for diﬀerence in predictions of HPV16 vaccination eﬀec-
tiveness between multi-site and uni-site models.
2. Material and methods
We developed two multi-site models and one uni-site model to ad-
dress our objectives.
2.1. Comparing predictions of HPV16 vaccination eﬀectiveness between
multi-site and uni-site transmission-dynamic models
2.1.1. Model structure
To address objective 1, predictions of HPV16 vaccination eﬀec-
tiveness are compared between a uni-site and a multi-site model. We
developed a uni-site and a multi-site deterministic HPV16 transmission
model based on the Susceptible-Infectious-Recovered paradigm (see the
Supplementary material for the ﬂow diagrams and the model equa-
tions). For both models, the population is 1) heterosexual, 2) open and
stable (deaths balance births), and 3) stratiﬁed according to gender and
two levels of sexual activity. Mixing between levels of sexual activity
was assumed to be random. For simplicity, we did not stratify the
models by age. On average, individuals spend 15 years in the modelled
population, representing the peak years of sexual activity (15–30
years).
The only structural diﬀerences between the uni-site and multi-site
models are in HPV16 transmission and natural immunity. The uni-site
model represents transmission between the cervico-vaginal site and
penis, and the probability of natural immunity following clearance is
allowed to vary between 0 and 100% in both women and men. On the
other hand, the multi-site model represents the following four trans-
mission pathways: 1) extragenital→ extragenital, 2) extragenital→
genital, 3) genital→ genital and 4) genital→ extragenital. In the multi-
site model, the extragenital site can either be the oral or anal site. Each
pathway has its own probability of transmission, which is modeled per
sexual partnership (i.e., we did not model duration of sexual partner-
ships, the speciﬁc number of diﬀerent acts within a partnership or use
transmission probabilities per act).
Scenarios with and without autoinoculation between the two sites
were investigated. With autoinoculation, individuals infected at one site
can get infected at the other site without sexual exposure, according to
two time-homogeneous rates corresponding to the two possibilities
(genital→ extragenital and extragenital→ genital). Given uncertainty
in the literature about natural immunity and the possible impact of
natural immunity assumptions on predictions, we modelled 4 scenarios.
In scenario 1, individuals can only acquire immunity upon clearing
genital infection and immunity protects against subsequent genital in-
fections, but not against extragenital infections (Local immunity after
genital infection only). In scenario 2, individuals can acquire local im-
munity upon clearing genital and extragenital infections (Local im-
munity after genital and extragenital infections). In scenario 3, individuals
can only acquire immunity upon clearing genital infection and im-
munity protects against subsequent infection at any site (Systemic im-
munity after genital infection only). Finally, in scenario 4, individuals can
acquire systemic immunity upon clearing genital or extragenital in-
fection (Systemic immunity after genital and extragenital infection).
2.1.2. Parameterization and ﬁtting procedure
To compare vaccination eﬀectiveness predictions between the uni-
site and multi-site models, the models were calibrated to the same pre-
vaccination HPV16 prevalence at the cervico-vaginal site (pre-
valence = 5.0–7.5%). The lower and upper bounds of HPV16 pre-
valence were based on estimates from two studies among US women
between 14 and 30 years old (around 5.0% (Hariri et al., 2011) and
7.5% (Wheeler et al., 2013)). In addition, the multi-site model was
calibrated to HPV16 prevalence representing either the oral (pre-
valence = 0.0–1.0% (Kreimer 2011; Gillison et al., 2012b)) or the anal
site (prevalence = 1.0–7.5% (Goodman et al., 2008; Nyitray et al.,
2011, 2015)) (see Table 1). We chose wide ranges for HPV16 pre-
valence at the extragenital sites to enable greater generalizability of
results. The models were calibrated to HPV16 prevalence by varying
HPV16 transmission probabilities from females to males and from
males to females. A maximum relative diﬀerence of± 15% was allowed
between male-to-female and female-to-male probabilities of transmis-
sion. In scenarios with autoinoculation, the two rates of autoinoculation
(genital→ extragenital and extragenital→ genital) were also varied
and assumed to be the same for males and females. All other parameters
were also identical between males and females and were ﬁxed based on
available data in the literature (Insinga et al., 2007, 2015) and prior
modelling work (Brisson et al., 2013) (see Table 1). To select the
parameters that produced the best ﬁt to the HPV16 prevalence data, we
used a 4 step procedure: 1) each parameter was given a uniform prior
(probability of transmission between 0 and 100%), 2) parameter sets
were drawn from the prior distributions using Latin Hypercube Sam-
pling (McKay et al., 1979; Van de Velde et al., 2012), 3) parameter sets
were selected if they produced HPV16 prevalence estimates within the
prespeciﬁed target intervals (see Table 1), and 4) the calibration pro-
cedure was stopped once about 2500 parameter sets were selected. The
uni-site model was calibrated a single time while the multi-site model
was calibrated eight times for each of the four diﬀerent scenarios of
natural immunity and the two scenarios of autoinoculation (with or
without).
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2.1.3. Analysis design and outcome
To investigate the eﬀect of multi-site transmission on estimates of
vaccination eﬀectiveness, we modelled a girls-only vaccination sce-
nario, assuming 100% vaccine eﬃcacy against infection (at all mod-
elled sites) and lifelong duration of protection.
For comparisons between the uni-site and multi-site model predic-
tions of vaccination eﬀectiveness, we used the relative reduction in
genital HPV16 prevalence at the post-vaccination equilibrium com-
pared to no vaccination. Results are presented using the median, the
minimum and maximum, the 25th and 75th percentiles of simulation
results using the 2500 parameter sets identiﬁed through calibration.
We assumed vaccination coverage was 40% in the base case, but
varied coverage between 0% and 100% in sensitivity analyses.
2.2. Understanding the eﬀect of the key factors of transmission responsible
for diﬀerence in predictions of HPV16 vaccination eﬀectiveness between
multi-site and uni-site models
To address objective 2, we proceeded in two steps:
2.3. Step 1: analysis with a simpliﬁed multi-site model
First, a simpliﬁed homogeneous multi-site model was used for
general tractability and theoretical insights. We identiﬁed three key
factors responsible for diﬀerences in HPV vaccination eﬀectiveness
predictions between the multi-site and uni-site models (see
Supplementary materials): 1) the proportion of all incident genital in-
fections that are due to extragenital→ genital transmission at pre-
vaccination equilibrium (Factor 1: proportion of genital infections
caused by extragenital infections); this proportion is obtained by di-
viding the incidence of genital infections caused by the transmission of
an extragenital infection to the genital site by the total incidence of
genital infections, 2) proportion of extragenital infections caused by
genital infections at pre-vaccination equilibrium (Factor 2), 3)
proportion of susceptibles to extragenital infections at pre-vaccination
equilibrium (Factor 3).
2.3.1. Model structure
The simpliﬁed multi-site model follows the same Susceptible-
Infected-Recovered structure as the model described in Section 2.1.1
(see Supplementary material for the model equations) with the four
transmission pathways modelled as probabilities per instantaneous
partnership. However, in contrast, the model includes one level of
sexual activity, one gender, no autoinoculation, and transmission from
individuals infected at the genital and extragenital sites occur in-
dependently (i.e., two independent modes of transmission).
2.3.2. Parameterization and ﬁtting procedure
We used the same values of duration of infection and probability of
natural immunity as for the model developed for objective 1 (see
Table 1). For simplicity, natural immunity was assumed to be local after
genital infections (which corresponds to scenario 1 in objective 1).
We aimed to assess the eﬀect of genital→ extragenital and extra-
genital→ genital transmission probabilities on predicted vaccination
eﬀectiveness. To do this, we calibrated the four transmission prob-
abilities to targets of 7% for endemic genital prevalence and 3% for
endemic extragenital prevalence. These targets were based on HPV16
prevalence targets for objective 1. The four transmission probabilities
were calibrated by solving algebraically the model equations to obtain
10 000 parameter sets.
2.3.3. Analysis design and outcome
For objective 2, we used the minimum vaccination coverage needed
to eliminate the infection in the population as our main outcome (the
elimination threshold, qc). We estimated the elimination threshold from
the basic reproductive number (R0). For the simple multi-site model,
the elimination threshold is given by −( )1 R10 . We computed R0 as the
leading eigenvalue of the Next-Generation-Matrix (Driessche and
Table 1
Uni-site and multi-site model calibration.
Multi-site model Uni-site model
Calibration target: HPV16 prevalence (females) Genital Genital
[5%-7.5%] (Hariri et al., 2011; Wheeler et al., 2013) [5%-7.5%] (Hariri et al., 2011; Wheeler et al., 2013)
Extragenital
[0%-7.5%] (Goodman et al., 2008; Kreimer et al., 2011; Nyitray et al.,
2011; Gillison et al., 2012, 2015)
Scenarios of natural immunity • Local immunity after genital infection,• Local immunity after genital and extragenital infection,• Systemic immunity after genital infection,• Systemic immunity after genital and extragenital infection
• Immunity after genital infection
Varying parameters Probabilities of transmissiona: Probabilities of transmissiona:
• Genital→ Genital,• Genital→ Extragenital,• Extragenital→ Extragenital,• Extragenital→ Genital
• Genital→ Genital
Rates of autoinoculation:
• Genital→ Extragenital,• Extragenital→ Genital
Average duration of infection:
Fixed parameters • 1.5 years (based on cervical HPV (Insinga, Dasbach et al., 2007)) Same values of ﬁxed parameters as in the multi-site
model
Eﬀective average rate of new partner acquisition per year (2015):
• Low level of activity (95%): 1.4• High level of activity (5%): 5.7
Probability of developing natural immunity after infection (Brisson,
Laprise et al., 2013):
• 45%
a Male-to-female and female-to-male probabilities of transmission were allowed to be diﬀerent (maximum relative diﬀerence allowed = ±15%). All other parameters were equal
between men and women.
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Watmough 2008).
2.4. Step 2: analysis with the heterogeneous multi-site model
In step 2, we assessed the eﬀect of Factors 1, 2 and 3 on predicted
HPV16 vaccination eﬀectiveness using the heterogeneous multi-site
model described in Section 2.1.1. To achieve this, we calculated, before
vaccination, from all the parameter sets identiﬁed during the calibra-
tion process in objective 1: the proportion of genital infections caused
by extragenital infections (Factor 1), the proportions of extragenital
infections caused by genital infections (Factor 2), and the proportion of
susceptibles to extragenital infections (Factor 3). We then examined the
relationships between these outcomes and HPV16 vaccination eﬀec-
tiveness.
3. Results
3.1. Comparing predictions of HPV16 vaccination eﬀectiveness between
multi-site and uni-site transmission-dynamic models
3.1.1. Eﬀect of multi-site transmission on vaccination impact assuming local
immunity only after genital infection (scenario 1) or local immunity after
genital infection and extragenital infection (scenario 2)
Under the assumption of local immunity after genital infection, the
impact of vaccination on the population-level prevalence of genital
HPV16 infection predicted by the multi-site model is similar to the uni-
site model when extragenital prevalence is low, but the multi-site
model predicts substantially greater vaccination eﬀectiveness when
extragenital prevalence is high (Fig. 1A and Table 2). The diﬀerence is
Fig. 1. Population-level vaccination eﬀectiveness of
HPV16 vaccination with a multi-site and uni-site
models: comparison by prevalence of extragenital
HPV16. Vaccination program is girls-only with 40%
coverage and vaccine is assumed to have 100% ef-
ﬁcacy and lifelong duration for the two sites of in-
fection. Vaccination eﬀectiveness = relative reduc-
tion in genital HPV16 prevalence at the post-
vaccination equilibrium compared to no vaccination.
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even greater when comparing the 75th quantiles or the maximum
predicted eﬀectiveness (Fig. 1A and Table 2). Finally, the inclusion of
autoinoculation caused a decrease in predicted eﬀectiveness by around
6 percentage points, assuming an extragenital prevalence between 3.0%
and 7.5%.
Under the assumption of local immunity after genital and extra-
genital infection, predicted eﬀectiveness with the multi-site model is
slightly greater than with the uni-site model when extragenital pre-
valence is low, and slightly lower when extragenital prevalence is high
(Fig. 1B and Table 2). As in scenario 1, the distribution of predicted
eﬀectiveness with the multi-site model is much more skewed toward
higher values (see Fig. 1B and Table 2). Overall, the diﬀerence in
predictions between the two models is lower in scenario 2 than in
scenario 1. Autoinoculation had little impact on predicted eﬀectiveness.
3.1.2. Eﬀect of multi-site transmission, assuming systemic immunity after
genital infection only (scenario 3) or systemic immunity after genital and
extragenital infection (scenario 4)
Under the assumption of systemic immunity after genital infection,
predictions with both models are almost identical with or without au-
toinoculation (Fig. 1C and Table 2). Under the assumption of systemic
immunity after genital and extragenital infections, predicted eﬀective-
ness with the multi-site model is lower than with the uni-site model
(Fig. 1D and Table 2). The diﬀerence between the uni-site and multi-site
models increases with higher extragenital prevalence. Autoinoculation
caused an increase in predicted eﬀectiveness up to 5 percentage points,
assuming an extragenital prevalence of 3.0%-7.5%.
3.1.3. Sensitivity analyses
The qualitative diﬀerences between the uni-site and multi-site
model predictions are not aﬀected by vaccination coverage as long as
coverage is below the elimination threshold (see Fig. S6 in
Supplementary materials). For example, under the assumption of local
immunity after genital infection (scenario 1), diﬀerences between the
uni-site and multi-site models start diminishing as coverage exceeds
50% (when the upper range of the multi-site model’s predictions reach
the elimination threshold) and disappear if coverage exceeds 75%
(elimination of HPV16 with both the uni-site and multi-site models).
3.2. Understanding the eﬀect of the key factors of transmission responsible
for diﬀerence in predictions of HPV16 vaccination eﬀectiveness between
multi-site and uni-site models
3.2.1. Eﬀect of inter-site transmission on the elimination threshold with the
simple homogeneous multi-site model
Fig. 2 shows that the elimination threshold decreases with in-
creasing extragenital→ genital transmission (Factor 1) and/or de-
creasing genital→ extragenital transmission (Factor 2). It can also be
extrapolated from Fig. 2 that the minimum elimination threshold de-
creases as the proportion of susceptibles to extragenital infection in-
creases (Factor 3). This result is stated in full and demonstrated in
Section 2.3 of the Supplementary materials. Brieﬂy, the minimum value
of the elimination threshold for the multi-site model (3% in Fig. 2) is
equal to 1-proportion of susceptibles to extragenital infections. Thus, if
the proportion of susceptibles to extragenital infections increases, 1-
Table 2
Predicted eﬀectiveness of vaccination against genital HPV16 infection for the multi-site and uni-site models by scenario and extragenital prevalence.
Multi-site Uni-site
Extragenital prevalence
[0%–1%] [1%–3%] [3%–5%] [5%–7.5%]
Scenario 1
with Autoinoculation 61%(58–64) 65%(62–71) 67%(63–72) 66%(61–71) 59%(57–62)
without Autoinoculation 61%(58–65) 67%(62–76) 73%(66–81) 72%(66–81)
Scenario 2
with Autoinoculation 62%(58–65) 64%(60–68) 61%(59–63) 56%(54–58) 59%(57–62)
without Autoinoculation 62%(58–65) 65%(61–70) 63%(60–66) 57%(59–61)
Scenario 3
with Autoinoculation 59%(57–62) 61%(59–64) 60%(57–62) 58%(56–61) 59%(57–62)
without Autoinoculation 61%(58–64) 62%(59–65) 61%(59–64) 60%(58–62)
Scenario 4
with Autoinoculation 58%(56–62) 57%(54–60) 54%(52–56) 50%(49–52) 59%(57–62)
without Autoinoculation 58%(55–61) 54%(52–56) 50%(49–51) 47%(47–48)
In the base-case, vaccination program is girls-only with 40% coverage and vaccine is assumed to have 100% eﬃcacy and lifelong duration for the two sites of infection. Models predictions
are presented as the median and intervals denote the 25th-75th percentiles of predictions.
Fig. 2. Eﬀect of transmission parameters on the
elimination threshold (qc) of the multi-site model.
The model was calibrated to a genital prevalence of
7% and an extragenital prevalence of 3%. The x-axis
represents probability that a male with an extra-
genital infection infects the genital site of his partner
during a partnership, and the y-axis represents the
probability that a male with a genital infection in-
fects the extragenital site of his partner during a
partnership. qc = elimination threshold, minimum
vaccination coverage needed to achieve elimination
assuming a vaccine with 100% eﬃcacy and lifelong
duration. Elimination threshold for the uni-site
model is given by the black line on the scale for the
elimination threshold.
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proportion of susceptibles to extragenital infections decreases and so
does the minimum elimination threshold. The maximum value of the
elimination threshold (38% in Fig. 2) is equal to 1-proportion of sus-
ceptibles to genital infections. Hence, the maximal value of the
elimination threshold for the multi-site model corresponds to the
elimination threshold of a uni-site model of the genital site, and the
minimal value to the elimination threshold of a uni-site model of the
extragenital site. In particular, if the proportions of susceptibles to
Fig. 3. Eﬀect of inter-site transmission and proportion of susceptibles to extragenital infection on average predicted eﬀectiveness with the multi-site model. A) Vaccination eﬀectiveness
as function of the proportion of susceptibles to extragenital infections and of the proportion of genital infections caused by extragenital infections (with autoinoculation), B) (without
autoinoculation), C) Vaccination eﬀectiveness as function of the proportion of genital infections caused by extragenital infections and of the proportions of extragenital infections caused
by genital infections (with autoinoculation), D) (without autoinoculation). IMPORTANTLY: In C) and D) we show the results for simulations where the proportion of susceptibles to
extragenital infections is higher than 90% (below this value there was no variability in vaccination eﬀectiveness). Vaccination eﬀectiveness = relative reduction in genital HPV16
prevalence at the post-vaccination equilibrium compared to no vaccination. Proportion of genital infections caused by extragenital infections = (Incidence of genital infections caused by
extragenital infections)/(Total incidence of genital infections). Incidence = (contact rate) x (probability of transmission) x (prevalence of infected) x (prevalence of susceptibles to genital
infections). OF NOTE: The median prediction of vaccination eﬀectiveness from the uni-site model is given by the black line on the vaccination eﬀectiveness scales. The relation between
variables was smoothed through local polynomial regression.
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genital and extragenital infections are the same, the elimination
threshold of the multi-site model will be the same as the elimination
threshold of the uni-site model.
In the Supplementary materials, we show analytically the results
presented above and that they are not dependent on speciﬁc parameter
values or assumptions of natural immunity.
3.2.2. Eﬀect of inter-site transmission and proportion of susceptibles to
extragenital infection on predictions of HPV16 vaccination eﬀectiveness
Fig. 3 shows HPV16 vaccination eﬀectiveness predictions of the
heterogeneous multi-site model as a function of the three key factors,
measured at pre-vaccination equilibrium: 1) the proportion of genital
infections that were caused by an extragenital infection, 2) the pro-
portion of extragenital infections that were caused by a genital infec-
tion, and 3) the proportion of susceptibles to extragenital infections.
The relationships are all monotonic with predicted vaccination eﬀec-
tiveness increasing when the proportion of susceptibles to extragenital
infections increases, when the proportion of genital infections caused
by extragenital infections increases, and when the proportion of ex-
tragenital infections caused by genital infections decreases. These re-
sults were the same when including autoinoculation or not.
4. Discussion
In this paper, we examined whether the predictions of traditional
uni-site models that were used to inform decisions about vaccination
are biased because they do not take into account transmission between
diﬀerent sites. Our results suggest that the diﬀerence between the
predictions of the uni-site and multi-site models are a function of nat-
ural immunity assumptions and prevalence at the extragenital site.
Under the assumption of local immunity (scenario 1 and 2), vaccination
eﬀectiveness predictions with the multi-site model are either equal or
greater than with the uni-site model. This diﬀerence increases when
assuming that a greater proportion of HPV16 genital infections was
produced by extragenital infections. Under the assumption that natural
immunity confers systemic protection against infection at all sites
(scenario 3 and 4), the multi-site model predictions of vaccination ef-
fectiveness were either the same or lower than the uni-site model pre-
dictions.
The eﬀects of natural immunity assumptions are essentially due to
diﬀerences in the proportions of susceptibles to genital infections and to
extragenital infections (Factor 3). The proportion of susceptibles to
extragenital infection is the highest under scenario 1 of local immunity
after genital infection, because there is no natural immunity to extra-
genital infections. Predicted eﬀectiveness is consequently highest under
scenario 1. The proportion of susceptibles to extragenital infection is
lower in scenario 3 (systemic immunity after genital infection) than
scenario 2 (local immunity after genital and extragenital infections) and
is the lowest in scenario 4 (systemic immunity after genital and extra-
genital infections). In scenario 3, the proportion of susceptibles to ex-
tragenital infection is roughly the same as the proportion of susceptibles
to genital infection, which explains why the multi-site and uni-site
models predict similar eﬀectiveness. Under scenario 4, the proportion
of susceptibles to genital infection is exceptionally lower than for the
uni-site model: natural immunity post-extragenital infection hinders the
transmission to genital sites.
Current evidence from the literature seems to lend more support to
the assumption of systemic immunity following clearance of genital
infection (scenario 3) (Carter et al., 2000; Brouwer et al., 2015a;
Giuliano et al., 2015). To our knowledge, there is no direct evidence
and no literature about the possibility of local immunity against HPV
infections (scenario 1 & 2). Yet, both the acquired humoral and cell-
mediated immune system could theoretically have site-speciﬁc diﬀer-
ences, which could result in greater natural immunity at the site of a
previous infection. For example, Tissue-Resident Memory T-cells could
be responsible for diﬀerential local immunity (Gebhardt and Mackay,
2012). On the other hand, vaccination should induce systemic HPV
immunity, which is supported by recent studies (Beachler et al., 2016).
Whether systemic immunity also extends to naturally acquired anti-
bodies remains unknown. If this was the case, systemic immunity would
be more likely following cervical HPV infection than infection at any
other sites, because the rate of seroconversion is the highest following
cervical infection and is very low for other sites of infection (Carter
et al., 2000; Brouwer et al., 2015a; Giuliano et al., 2015). Thus, the
higher rate of seroconversion in women should result in greater pro-
tection of women against extragenital HPV infections, and this has been
proposed as an explanation for the gender-diﬀerence in oral HPV pre-
valence (Gillison, Broutian et al., 2012). However, a protective eﬀect of
antibodies on acquisition of extragenital infections has not yet been
demonstrated (Beachler et al., 2015; Pierce Campbell et al., 2016).
Furthermore, prevalence of anal HPV is not lower in women compared
to men, but this could be due to a strong correlation in the timing of
anal and genital HPV acquisition in women (hence women may acquire
anal HPV before acquiring natural immunity).
Our study is the ﬁrst to calibrate a multi-site model to HPV pre-
valence to assess diﬀerences in predicted eﬀectiveness with traditional
uni-site models. To our knowledge, two multi-site models have been
published (Heijne et al., 2017; Brouwer et al., 2015b; Hui et al., 2015),
and none of which has examined the impact of vaccination. In parti-
cular, Brouwer et al. (Brouwer et al., 2015b) have shown that a sub-
stantial bias can occur by calibrating a model without autoinoculation if
the true model generating the data has autoinoculation. Our results
show that models with autoinoculation predict lower eﬀectiveness than
models without autoinoculation in some speciﬁc contexts (e.g., when
the proportion of individuals susceptible to genital infections is similar
to the proportion of those susceptible to extragenital infections).
However, the eﬀect of autoinoculation was much lower than in the
theoretical example presented in Bouwer et al. This may be because
Bouwer et al., did not include natural immunity in their models and did
not calibrate their model to endemic prevalence of HPV. Hui et al. (Hui
et al., 2015) have shown that pharyngeal and anal infections by go-
norrhea can explain the substained transmission to the urethral site in a
Men-who-have-Sex-with-Men population in which transmission occurs
through oral⇔genital, oral⇔anal, and anal⇔genital contacts. They are
able to show that transmission of gonorrhea can be disrupted by pre-
venting only oral⇔genital transmission. Unlike the work of Hui et al.
(Hui et al., 2015), we cannot determine from the calibration we per-
formed whether a speciﬁc HPV transmission pathway (e.g., genital→
oral autoinoculation) is essential or important for sustained transmis-
sion of HPV infections. This would require further knowledge on the
relevant modes of HPV transmissions which could include non-pene-
trative acts such as kissing or sexual touching.
This study has three main limitations. First, for simplicity, we ca-
librated our modeIs using probabilities of HPV transmission, while
other parameters remained ﬁxed at values extracted from the literature.
We examined diﬀerent assumptions (and values) of natural immunity.
Varying the probability of natural immunity aﬀects the proportion of
susceptibles to infection at the diﬀerent sites. We observed that in-
creasing the probability of natural immunity to extragenital infections
from 0% (scenario 1) to 45% (scenario 2) decreased the proportion of
susceptibles to extragenital infections and thus decreased predicted
eﬀectiveness with the multi-site model. Varying clearance rates also
aﬀects the proportion of susceptibles: for a given prevalence of infec-
tion, increasing clearance rates increases the proportion of immune
individuals and decreases the proportion of susceptibles. Second, we
assumed near-symmetrical transmission parameters between women
and men. We show in the Supplementary materials that there may be
additional dynamics to consider when the prevalences are highly
asymmetrical between women and men, but the bounds on the elim-
ination threshold we observed in Fig. 2 would not change. Finally, we
did not include speciﬁc sexual acts (e.g., oral sex) in our model, which
implies that there is no within-individual correlation in sexual
P. Lemieux-Mellouki et al. Epidemics xxx (xxxx) xxx–xxx
7
practices.
HPV may be able to infect other sites than the anal, genital and oral
canals. For instance, nails are known to harbor HPV DNA and sub-
ungual cancers have been attributed to HPV16 (Moy et al., 1989). The
inclusion of these other sites of infection in HPV models could aﬀect
predictions of vaccination eﬀectiveness against genital infection only if
infections at these sites can be transmitted to the genital site (even
indirectly) or if they contribute to natural immunity to genital infec-
tions. Some of the results presented here can be generalized to any
number of sites. Thus, if the simple multi-site HPV model was to include
three or more sites of infection (e.g., genital, oral and anal), predicted
eﬀectiveness would be in-between eﬀectiveness predicted with two uni-
site models of the two sites with the highest and lowest proportions of
susceptibles. However, for the heterogeneous multi-site model of ob-
jective 1, the minimum predicted eﬀectiveness with the multi-site
model can theoretically be lower than the eﬀectiveness predicted with a
uni-site model ﬁtted to genital HPV (the site with the lowest proportion
of susceptibles) as shown in Fig. 1B. This phenomenon can be ampliﬁed
with additional sites (see Supplementary materials).
5. Conclusions
In conclusion, for the assessment of vaccination eﬀectiveness
against genital infections and diseases, multi-site transmission of HPV is
important to model if: 1) a signiﬁcant proportion of genital infections
originates from an extragenital site, or 2) extragenital infection con-
tributes signiﬁcantly to the natural immunity against genital infection.
Currently, there is no strong evidence that extragenital infections are a
reservoir for genital infections in heterosexual transmission of HPV or
that natural immunity following extragenital infections would protect
against future genital infections. Hence, the possibility of a strong bias
from using a uni-site model to assess vaccination eﬀectiveness against
genital HPV16 in women is unlikely given our current understanding of
the natural history of HPV infection.
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